Search for: "LUPIN PHARMACEUTICALS, INC." Results 101 - 120 of 120
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
7 Dec 2023, 1:47 pm by Dennis Crouch
Teva Pharmaceuticals USA, Inc., 7 F.4th 1320, 1333 (Fed. [read post]
8 Feb 2011, 10:51 pm by Marie Louise
(FDA Law Blog) US: Another academic with solutions to problems that don’t exist (Patent Docs) US: Syngenta files for declaratory judgment of invalidity and non-infringement of Bayer’s patents based on its development of GM crops containing HPPD gene (Patent Docs) US: District Court New Jersey: Loss of market share to infringing competitor during six year reexamination warrants denial of stay: Wyeth et al v Abbott (Docket Report) US: District Court New Jersey: Court precludes jury… [read post]
15 Jul 2009, 5:15 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: European Commission Competition DG releases final report on pharmaceutical sector (IPKat) (PatLit) (BLOG@IP::JUR) (IAM) (Managing Intellectual Property) (Intellectual Property Watch) (The SPC Blog) (IAM) US: Follow-on biologics proposals considered by US Senate HELP Committee; Committee passes amendment for 12-year biologics exclusivity period… [read post]
3 Mar 2010, 5:05 am
(IP Osgoode) Australia: University of Western Australia’s application to appeal FCAFC’s decision in University of Western Australia v Gray fails (IP Whiteboard) Colombia/EU/Peru: Tough IP health provisions in Europe’s Colombia/Peru trade deal (IP Watch) (IP tango) EU: Something more about Swiss type claims: G02/08 (SiNApSE) (SiNApSE) US: Pharmaceutical patent settlements – and what about patients? [read post]
3 Mar 2010, 5:05 am
(IP Osgoode) Australia: University of Western Australia’s application to appeal FCAFC’s decision in University of Western Australia v Gray fails (IP Whiteboard) Colombia/EU/Peru: Tough IP health provisions in Europe’s Colombia/Peru trade deal (IP Watch) (IP tango) EU: Something more about Swiss type claims: G02/08 (SiNApSE) (SiNApSE) US: Pharmaceutical patent settlements – and what about patients? [read post]
9 Feb 2009, 11:32 pm
(alleged infringers)Eli Lilly's (patent owner) Cymbalta drugAstraZeneca's (patent owner) Crestor drugPenwest Pharmaceuticals (patent owner) Opana ER drugSepracor's (patent owner) Xyzal drugOf Apple and US 7,479,949, see the IPBiz post Obvious? [read post]
7 Apr 2010, 4:30 am
Sandoz Pharmaceuticals GmbH et al (EPLAW) Prilosec (Omeprazole) – US: AstraZeneca ordered to pay attorney’s fees for ‘baseless’ suit to protect Prilosec OTC: AstraZeneca AB et al. v. [read post]
3 Aug 2011, 3:31 am by Marie Louise
Patent and Trademark Office (Holman’s Biotech IP Blog) US: Myriad writes to CAFC on standing issue (Patent Docs) (Patent Docs) (Holman’s Biotech IP Blog) US: In the first 7 months of 2011, the FDA has approved 18 new molecular entity pharmaceutical drugs (and no biologic NMEs) (KEI) US: Embryonic stem cell funding suit dead: Sherley v. [read post]
27 Jan 2010, 3:00 am
Lupin Ltd. concerning LoSeasonique and Takeda Pharmaceutical Company Limited et al v. [read post]
24 Feb 2010, 2:11 am
(Patent Docs) US: PhRMA representative questions follow-on biologics paper (Patent Docs) USPTO announces agenda for next biotechnology/chemical/pharmaceutical customer partnership meeting (Patent Docs)   Products Arzerra (Ofatumumab) – US: Glaxo Group, GlaxoSmithKline seek declaratory judgment of invalidity and non-infringement against Genentech, City of Hope (Patent Docs) Cipro (Ciprofloxacin) – US: Bayer files patent infringement complaints against Lupin in… [read post]
24 Feb 2010, 2:11 am
(Patent Docs) US: PhRMA representative questions follow-on biologics paper (Patent Docs) USPTO announces agenda for next biotechnology/chemical/pharmaceutical customer partnership meeting (Patent Docs)   Products Arzerra (Ofatumumab) – US: Glaxo Group, GlaxoSmithKline seek declaratory judgment of invalidity and non-infringement against Genentech, City of Hope (Patent Docs) Cipro (Ciprofloxacin) – US: Bayer files patent infringement complaints against Lupin in… [read post]
13 Jun 2008, 3:40 am
: (Patent Docs), Generic drug developers will continue to take advantage of global demand for lower-priced drugs, with Teva poised to maintain lead position says Goldman Sachs analyst: (GenericsWeb), Daiichi Sankyo takeover of Ranbaxy: (Profitability through Simplicity), (Spicy IP), (GenericsWeb), Canada: Generics to penetrate 26% pharma market in Canada says RNCOS research: (GenericsWeb), Canada: Generic drug makers spreading misinformation about patent regulation amendments to dodge real story:… [read post]
30 May 2008, 9:09 am
: (Spicy IP), India: DCGI preparing document to implement patent-registration linkage: (Spicy IP), New Zealand: Generic pharmaceutical companies taking advantage of NZ IP laws and medicines regulations: (International Law Office), Uganda: Cipla licenses ARV technology into Uganda: (Afro-IP), US: Money saved through generic prescriptions: (GenericsWeb), US: Government plans to keep close tab on drug patent settlements: (GenericsWeb), US: FTC reports 14 deals to delay generics in 2007:… [read post]
2 May 2008, 7:00 am
: Lupin v Abbott Labs: (FDA Law Blog), Plavix (Clopidogrel) – US: Apotex sues FDA to recover 180-day exclusivity on generic Plavix: (Orange Book Blog), Plavix (Clopidogrel) – US: Former Bristol-Myers Squibb executive charged over lying about Plavix deal struck with rival Apotex: (Managing Intellectual Property), Risperdal (Resperidone) – US: Apotex files motion to intervene in relisting of Risperdal patent case; Teva quickly files opposition: Teva… [read post]
18 Apr 2008, 2:00 am
: RealNetworks, Mattel and Hasbro copy the infringer by creating online Scrabble: (IP ThinkTank), Creative Commons Statement of Intent for Attribution-Share Alike Licenses released: (creativecommons.org) Events IP Business Congress – 25-26 June, Amsterdam: (IP Business Congress), INTA annual meeting – 17-21 May, Berlin: (IMPACT), Australia: IPRIA / CELRL / IP Australia: Employees’ IP and the employment relationship – incentives to innovate… [read post]